Burst Biologics

Burst Biologics is a research-focused biotechnology company that develops groundbreaking products in the cutting-edge field of regenerative medicine. An in-house team of Ph.D. scientists is focused on researching large molecule pharmaceuticals and the potential to impact life-altering conditions. At Burst, product quality is a top priority. Burst's onsite laboratory maintains control of each production stage to ensure optimal consistency and quality in every product. Burst Biologics provides premium products for both surgical and clinical applications. Tissue products offered by Burst have three main composition components: umbilical cord blood (UCB), cancellous bone, and amniotic tissue.

Clinomics

The Page for The Leading Company in Precision Medicine for Genome-Based Life, Medical, and Health Care.

Aileron Therapeutics

Aileron is a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients' lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients' quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy. Our vision is to bring chemoprotection to patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. Visit us at aileronrx.com to learn more.

Etaluma, Inc.

Etaluma has revolutionized fluorescence microscopy by replacing the oculars with a computer screen, the arc lamp with LEDs, the CCD camera with a CMOS and greatly simplified the design. A short and simple optics path yields resolution and sensitivity that beats the big 4. The compact and low power microscope modules can be integrated into clinical and research instruments. We offer a custom platform development architecture that's greatly accelerates instrument development for our partners. Follow our CEO, Chris Shumate, for weekly posts on microscopy here: https://www.linkedin.com/in/chris-shumate-753566/

UNI PET CLINIC, INC.